focus -WSS

focus

author：entertainment 2025-09-30 00:49:31 - browse：5

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Ohio still needs to do more to protect the right to abortion

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Venture capital firm's plans to take over Akron hospital face hurdles

Health Care Service Corp to buy Cigna Medicare Advantage plans

New clues to why women have higher risk of autoimmune disorders

Boston competes with Raleigh

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

focus

entertainment

Cancer drug shortages should be causing more outrage

Why Medicare shouldn’t cover every FDA

Novavax promises a turnaround & Lilly roils the obesity market

Today's health inequities arise from racist U.S. history, say experts

Jerome Adams on the need for new antivirals for Covid

A letter from the executive editor: STAT UnitedHealth investigation

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Peter Hotez and the public health issue of online harassment

Pancreatic cancer early detection could be helped by AI

hotspot

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Experimental asthma app from Apple and Anthem shows promise

Publishing genetic code of viruses could cause disaster

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Why you shouldn’t ask, “What country has the best health care?”

focus

leisure time

hotspot

knowledge